TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA and Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. EP Europace. Oxford: Oxford University Press, 2021, vol. 23, No 4, p. 539-547. ISSN 1099-5129. Available from: https://dx.doi.org/10.1093/europace/euaa261.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation
Authors TABORSKY, Milos (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic), Josef KAUTZNER (203 Czech Republic), Marek VICHA (203 Czech Republic), Renata AIGLOVA (203 Czech Republic), Vit GLOGER (203 Czech Republic), Marian FEDORCO (203 Czech Republic), Jaroslav DUBA (203 Czech Republic), Lukas DUSEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Monika BEZDEKOVA (203 Czech Republic) and Tomas SKALA (203 Czech Republic, guarantor).
Edition EP Europace, Oxford, Oxford University Press, 2021, 1099-5129.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.486
RIV identification code RIV/00216224:14110/21:00121729
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/europace/euaa261
UT WoS 000644500900009
Keywords in English Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 8/6/2021 11:04.
Abstract
Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.
PrintDisplayed: 25/5/2024 13:24